Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-in.

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated risks in patients.

Geron's blood disorder drug gets FDA advisers' backing

The U.S. health regulator's staff on Tuesday flagged concerns that the late-stage trial data on Geron's anemia drug does not show whether the risks of treatment with imetelstat are outweighed by the potential benefit, documents released ahead of a meeting of independent experts showed.

US FDA staff flags concerns about Geron's anemia treatment

Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes. The company reported a loss from operations of $194 million in 2023, with $378.1 million in cash at the end of the year. Geron stock has risen by 12% since December, but faces potential risks from an upcoming FDA Advisory Committee meeting and competition from Bristol-Myers Squibb's Reblozyl.

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript February 28, 2024 8:00 AM ET

Geron Corporation (GERN) Q4 2023 Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023. “Geron's progress and execution throughout 2023 has paved the way for a potentially transformational 2024, as we plan for the transition to becoming a commercial compan.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m.

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET. A webcast of the presentation will be available through the Investors and Media section of Geron's website under Events following the pre.

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Geron (GERN) Upgraded to Buy: Here's Why

iSun

LiveOne

Terawulf

Penny stocks are the jittery nerves of the stock market – even minor news events can make them swing unpredictably. By definition, penny stocks are shares of companies traded below $5 per share and display extreme percentage changes from relatively insignificant moves in price.

Penny Stocks To Buy? 4 To Watch Before Next Week

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial evaluating first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS), as well as population analysis of claims data in lower risk MDS. The data were presented at the American Society of Hematology (ASH) Annual Meeting, taking place from.

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company's first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF). “Reaching fifty percent enrollment in IMpactMF is an important milestone towards the completion of this first-of-.

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Corporation has submitted its New Drug Application (NDA) to the FDA for its lead candidate, imetelstat, for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes. The FDA has accepted Geron's NDA and will convene an Advisory Committee to discuss the suitability of imetelstat for approval. The PDUFA date occurs in June 2024. GERN stock price is declining today despite the publication of positive Phase 3 data in The Lancet, potentially due to concerns about competition from Bristol Myers Squibb's Reblozyl.

Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date. “The Lancet's publication of ou.

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company's Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level.

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2023 Healthcare Conference Tuesday, November 14th at 9:10 a.m. ET (Fireside Chat) Piper Sandler 35th Annual Healthcare Conference Tuesday, November 28th at 9:30 a.m. ET (Corporate Presentation) 6th Annual Evercore ISI.

Geron to Participate at Upcoming Investor Conferences in November

Agnico Eagle Mines

Aspen Aerogels

Corteva Inc

Mobileye Global Inc

CarParts.com, Inc.

Quanterix

While enough evidence exists that justify a pessimistic view of the market – in particular, high inflation and high borrowing costs – it's also possible that a hot November could rejuvenate previously embattled stocks to buy. And that's not an entirely speculative proposition.

7 Stocks to Buy if You Anticipate a Hot November

Geron Corporation (NASDAQ:GERN ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Corporate Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman, President and Chief Executive Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Michelle Robertson - Executive Vice President and Chief Financial Officer Conference Call Participants Tuuli Tsogtbaatar - Stifel Craig Miller - Goldman Sachs Kalpit Patel - B. Riley Ethan Markowski - Needham & Company Joel Beatty - Baird Operator Good morning.

Geron Corporation (GERN) Q3 2023 Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San D.

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the third quarter of 2023. “This quarter, we continued to make important progress and build momentum along our planned path to develop and commercialize imetelstat, which is now the first telomerase inhibitor to be under.

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its third quarter 2023 financial results and business highlights before the market opens on Thursday, November 2, 2023 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 9:00 a.m. ET the same day.

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetelstat has a PDUFA on June 16, 2024, with an advisory committee meeting expected before that date. The FDA's request for an advisory committee meeting suggests that the approval for imetelstat may not be straightforward.

Geron Corporation Stock: Another Buying Opportunity

Coeur Mining

VAALCO Energy

Evolus

Nerdy

Planet Labs

Taboola

While targeting small-cap stocks to buy might not be the go-to recipe for predictable and consistent market success, in some cases, you just have to do what you have to do. Think of it this way.

7 Must-Own Small-Cap Stocks That Could Outperform the Market

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). The MAA was submitted earlier this month and is now under regulatory review by.

News for Geron Stock (GERN)